On February 27, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the vaccine developed by Johnson & Johnson for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).